New pain tablet could replace IV opioids in ERs

NCT ID NCT06917651

Recruiting now Symptom relief Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a 30-microgram sublingual sufentanil tablet for treating moderate to severe pain from a single injury in the emergency department. 300 adults with pain scores of 4 or higher on a 0-10 scale will receive either the tablet or standard pain treatment. The goal is to see if the tablet works faster and better than usual care, without needing an IV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sublingual sufentanil 30 mcg tablet
What this could lead to: If it works, this could provide a faster, non-invasive way to manage severe pain in emergency settings without needing an IV.
What could go wrong: This is a single-center Phase 3 trial, so results may not apply everywhere. The drug is already approved, but it may not be clearly better than standard care and could cause side effects like drowsiness or nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAIN MANAGEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAIN MANAGEMENT

Contacts and locations

Locations

CHU de Clermont-Ferrand, Clermont-Ferrand
RECRUITING

France, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.